Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Delivering the FY2026-FY2027 revenue runway while preserving cash-backed profit could extend growth beyond the Base-case fade.
Provider-adjusted normalized net margin remains below 9% by FY2028.
Sell. Ordinary investors should avoid new exposure and reduce existing holdings because the report-date price stands well above our Fair value and Potential value.
The report was prepared at $941.95 on 2026-09-04. Fair value is $410.01 and Potential value is $495.63 as of 2026-09-08, implying -56.47% to Fair value.1
The main risk is normalized net margin below 9% by FY2028. Weaker pricing or mix would reduce earnings and operating cash, while a lower valuation multiple would deepen the loss.
The clearest upside is delivery of the FY2026-FY2027 revenue runway with durable cash-backed profit. That would raise the future earnings base, but it would not by itself justify the report-date price.
The demand-led upside is continued revenue acceleration through FY2027, followed by a controlled fade rather than an abrupt slowdown.
Sell because the accepted operating upside does not support the report-date valuation.
The demand-led upside is continued revenue acceleration through FY2027, followed by a controlled fade rather than an abrupt slowdown.
Sell because the accepted operating upside does not support the report-date valuation.
products and services that generate, transfer, orchestrate, convert, and store electricity. GE Vernova Inc. designs, manufacture, deliver, and service The commitments primarily consist of obligations to make investments by its Financial Services business. See Note 21 for further
Its Electrification segment includes grid solutions and power conversion & storage, which the company collectivelies refer to as •Its Electrification segment includes grid solutions, power conversion, electrification software, and solar and storage solutions
The harshest coherent path combines weaker normalized margins with a peer-like valuation. Lower earnings and a lower price paid per earnings dollar reinforce each other.
The moat is not established. Near-term growth, improving profit, and peer margins do not demonstrate switching costs, installed-base lock-in, protected pricing, or service advantages.
PH and EMR test higher-margin economics, ETN tests growth, and CMI tests lower-margin economics. Their different profiles make the set a valuation and operating cross-check, not proof of customer alternatives.
FY2025 net income and stronger cash backing show improved economics. These are business outcomes, not evidence of a structural moat.2
The highlighted cell is Fair value when every assumption sits at its base level ($410.01). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $442.3M after modeled capex of $1.3B, with terminal value at 60.4% of . A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
A beat matters only if revenue, normalized profit and operating cash improve together.
Meeting the near-term outlook does not resolve the report-date valuation premium.
The machinery benchmark showed capital spending at 4.1% of revenue and 0.68x depreciation as of 2026-09-01.
The demand-led upside is continued revenue acceleration through FY2027, followed by a controlled fade rather than an abrupt slowdown.
The cycle weakens if demand conversion slows while competitors preserve stronger margins. That would pressure both project share and pricing.
No new allocation. The report-date price exceeds both Fair value and Potential value, while execution must remain strong to sustain the premium.1
Continue to avoid new exposure while the price is outside our fair-value range. Sell remaining exposure if FY2027 revenue growth falls below 8% or FY2028 normalized net margin stays below 9%.
The report-date price stands above Potential value, leaving inadequate support even if near-term growth is delivered.1
Reduce exposure while valuation remains above the accepted range. Do not rely on continued multiple expansion.
The FY2026-FY2027 runway is attractive, but explicit duration beyond FY2027 is limited and competitors provide demanding benchmarks.
Fair value is $410.01 and Potential value is $495.63, both below the $941.95 report-date price.1
The operating recovery is genuine, but the report-date share price requires stronger and longer growth than the forecast supports.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Lower sales growth reduces the earnings base, while weaker pricing or mix cuts profit per sales dollar. Paying less for future earnings compounds the decline.
If provider-adjusted normalized net margin remains below 9% by FY2028, weaker pricing or mix and normalized taxes reduce earnings and operating cash.
If the terminal P/E falls below 18.944x, investors pay less for each dollar of future earnings. Capital loss can follow even while profit remains positive.
The five developments that would weaken our investment case.
Weaker pricing or mix would cut profit per sales dollar, reduce operating cash, and invalidate the assumed earnings-conversion path.
Current:FY2028 planned normalized margin: 12%.
Alert ifBelow 9% by FY2028.
A lower multiple means investors pay less for each dollar of future earnings, causing capital loss even if profit remains positive.
Current:38.17x forward earnings as of 2026-09-08.
Alert ifTerminal P/E below 18.944x.
A sustained shortfall would show weaker demand conversion, pricing, capacity execution, or competitive share, reducing the later earnings base.
Current:FY2027 estimate implies 13.89% annual growth.
Alert ifBelow 8% for FY2027.
Poor cash backing would indicate that reported profit is not translating into funds available for reinvestment, distributions, or balance-sheet support.
Current:FY2025 operating cash was $1.02 for each $1 of reported profit.
Alert ifBelow $0.80 for each $1 of reported profit for two fiscal years.
A decline in Europe’s attributed revenue would reduce that region’s contribution to consolidated sales. The effect on total growth would depend on performance in other geographies.
Current:FY2025: $7.59 billion.
Alert ifBelow $5 billion in FY2027.
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Limitation: Terminal value is 71.3% of this model's value, above the 60% level at which the methodology flags concentration; the value leans on the years beyond the explicit forecast.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
This path preserves the operating recovery but does not assume protected pricing or an extended period of rapid growth. A sustained shortfall against the FY2027 outlook would disconfirm it.
Evidence would be continued estimate delivery, cash-backed profit and new demand visibility beyond FY2027. Weaker normalized margins or higher reinvestment would disconfirm this path.
A broad miss would shorten the growth runway and reduce future earnings.
FY2025 operating cash slightly exceeded reported profit. This supports earnings backed by cash, but it does not prove that profit margins will remain durable.
It tests whether the explicit demand runway survives.
It shows whether sales become durable profit and cash.
Weak cash backing would lower funds available to shareholders.
Stronger peers can pressure project share and pricing.
| $33.01B |
| $29.65B |
| $33.24B |
| $34.94B |
| $38.07B |
| +3.6% |
| Gross profit | $4.95B | $3.46B | $4.82B | $6.09B | $7.54B | +11.1% |
| Operating income | $-692.0M | $-2.88B | $-923.0M | $471.0M | $1.39B | — |
| Net income | $-633.0M | $-2.74B | $-438.0M | $1.55B | $4.88B | — |
| EPS (diluted) | — | $-10.00 | $-1.60 | $5.58 | $17.69 | — |
| EBITDA | $484.0M | $-526.0M | $932.0M | $3.56B | $3.68B | +66.1% |
| R&D | $1.01B | $979.0M | $896.0M | $982.0M | $1.20B | +4.4% |
| SG&A | $4.82B | $5.36B | $4.85B | $4.63B | $4.95B | +0.7% |
The shift from FY2021 cash losses to FY2025 cash-backed profit improves business quality. Durability depends on margin normalization and continued conversion of reported profit into operating cash.1
Diluted average shares were 274 million in FY2023, 278 million in FY2024 and 276 million in FY2025. Dilution was not one-directional, so share count requires continued tracking.
The record establishes an operating recovery, but that should not be presented as a dated return-on-invested-capital trend.
No verified spread is presented. The evidence supports improving earnings and cash generation, not a separate return-on-capital conclusion.
FY2021 operating income was negative $884 million. FY2025 net income was positive $4.88 billion.
The turnaround is real, but normalized margins still determine whether it becomes durable compounding.
FY2021 free cash flow was negative $2.24 billion. FY2025 operating cash slightly exceeded reported profit.
Cash-backed profit supports the operating inflection, but a sustained drop below $0.80 per $1 of profit would weaken it.
| Revenue | $38,068,000,000 |
|---|---|
| Cost of revenue | $30,533,000,000 |
| Gross profit | $7,535,000,000 |
| Operating expenses | $6,147,000,000 |
| Operating income | $1,388,000,000 |
| Non-operating items and tax | $3,496,000,000 |
| Net income | $4,884,000,000 |
| Total assets | $63,016,000,000 |
|---|---|
| Cash | $8,848,000,000 |
| Current assets | $40,216,000,000 |
| Total liabilities | $50,720,000,000 |
| Current liabilities | $40,972,000,000 |
| Shareholders’ equity | $12,296,000,000 |
| Net income | $4,884,000,000 |
|---|---|
| Operating inflow | $5,737,000,000 |
| Depreciation and amortization | $853,000,000 |
| Operating cash flow | $4,987,000,000 |
| Operating outflow | $750,000,000 |
| Cash available | $13,416,000,000 |
| Beginning cash | $8,205,000,000 |
| Exchange-rate effect | $224,000,000 |
| Investing outflow | $755,000,000 |
| Financing outflow | $3,813,000,000 |
| Share repurchases | $3,316,000,000 |
| Dividends paid | $275,000,000 |
| Other financing activities | $222,000,000 |
| Ending cash | $8,848,000,000 |
| Investing cash flow | -$755,000,000 |
| Financing cash flow | -$3,813,000,000 |
Source: SEC EDGAR · Filed 2026-01-29 · SEC EDGAR
| Revenue by geography | Revenue | Share | YoY |
|---|---|---|---|
| United States | $17.3B | 45.6% | 18.1% |
| Europe | $7.6B | 19.9% | -8.8% |
| Middle East And Africa | $5.4B | 14.2% | 28.5% |
| Asia | $4.6B | 12.2% | -1.5% |
| Americas Excluding U.S. | $3.1B | 8.2% | 2.6% |
Point-in-time financial data used in the 2026-09-08 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | $33B | $484M | -$633M | -$1.7B | -$2.2B | $577M | $1.2B | -$3B | — | — | — | -$1.1B | $2B | — | $1.8B | $1.8B | — | -2.7% | — | — | — |
| 2022-12-31 | $29.7B | -$526M | -$2.7B | -$114M | -$627M | $513M | $991M | -$3B | — | — | $15M | -$322M | $811M | $1.8B | $2.1B | $2.1B | $1.7B | -9.7% | — | — | — |
| 2023-12-31 | $33.2B | $932M | -$438M | $1.2B | $442M | $744M | $964M | -$3.9B | $0 | $0 | $16M | -$734M | -$408M | $2.1B | $1.6B | $3.6B | $1.7B | -2.8% | — | — | — |
| 2024-12-31 | $34.9B | $3.6B | $1.6B | $2.6B | $1.7B | $883M | $1.2B | — | $43M | $0 | -$23M | -$37M | $3.7B | $1.6B | $4.2B | $4.2B | $1.6B | 1.3% | — | 9.3% | — |
| 2025-12-31 | $38.1B | $3.7B | $4.9B | $5B | $3.7B | $1.3B | $853M | — | $3.3B | $275M | $0 | -$755M | -$3.8B | $8.2B | $8.8B | $9.3B | $1.2B | 3.6% | — | 9.0% | — |
GE Vernova Inc. (GEV) trades at 38.2x forward earnings against a peer median of 22.8x. Its EV/EBITDA of 61.9x compares with a peer median of 19.7x. The comparison uses 4 peers: Parker-Hannifin Corporation, Eaton Corporation plc, Emerson Electric Co. and Cummins Inc., as of 2026-09-08.
| Geographic demand breadth | positive | Europe, Asia, Middle East and Africa, and the Americas outside the United States were material FY2025 revenue sources. |
| Growth maturation | neutral | The accepted path expects the near-term surge to fade toward mature growth after FY2027. |
FY2025 revenue came from the United States and four disclosed international regions. This shows demand breadth, but not regional margins or supply-chain exposure.3
| Why |
|---|
| Share price above Potential value. | Avoid new exposure and reduce existing exposure. | Even the favorable end of the accepted range remains below the report-date price. |
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
| Eaton Corporation plc |
| 25.6x |
| 5.3x |
| 27.2x |
| 19.7% |
| 16.6% |
| EMR | Emerson Electric Co. | 21.1x | 4.6x | 16.0x | 12.8% | 26.9% |
| CMI | Cummins Inc. | 16.3x | 2.2x | 16.5x | 21.1% | 11.9% |
